Page 1 | Search Results | Blood | American Society of Hematology

1-19 of 19

Sort by

Sort Order Select

Journal Articles

NAMPT Inhibitor KPT-9274 Selectively Targets Self-Renewal Capacity in Acute Myeloid Leukemia

Shaneice Renee Mitchell, BS, Nicole Grieselhuber, MD PhD, Yerdanos Asemelash, Matthew Cannon, BA, Shelley Orwick, BS, Pratibha Sharma, PhD, Virginia Goettl, DVM, PhD, Vinay K Puduvalli, MD MBBS, Deepa Sampath, PhD, Alice S. Mims, MD, James S. Blachly, MD, Amy M. Lehman, PhD, Bonnie K. Harrington, DVM, Justin Breitbach, Erkan Baloglu, William Senapedis, PhD, Rosa Lapalombella, PhD, John C. Byrd, MD

Blood (2018) 132 (Supplement 1): 3931.

https://doi.org/10.1182/blood-2018-99-119358

Published: 2018

Journal Articles

PAK4 Inhibition Impacts Growth and Survival, and Increases Sensitivity to DNA-Damaging Agents in Waldestrostom Macroglobulinemia

Na Li, MD, Mariateresa Fulciniti, PhD, Michael A Lopez, BS, Tommaso Perini, MD, Raphael Szalat, MD, Subodh Kumar, PhD, Mehmet Kemal Samur, PhD, Lian Xu, Yan Xu, MD, William Senapedis, PhD, Erkan Baloglu, Stefania Oliva, MD, Masood A. Shammas, PhD, Zachary Hunter, PhD, Kenneth C Anderson, MD, Steven P Treon, MDPhDFRCP, Nikhil Munshi, MD

Blood (2017) 130 (Supplement 1): 648.

https://doi.org/10.1182/blood.V130.Suppl_1.648.648

Published: 2017

Journal Articles

Eltanexor (KPT-8602), a Second-Generation Selective Inhibitor of Nuclear Export (SINE) Compound, in Patients with Refractory Multiple Myeloma

Robert Frank Cornell, MD, Adriana C. Rossi, MDMSc, Rachid Baz, MD, Craig C Hofmeister, MDMPH, Chaim Shustik, MD, Joshua R Richter, MD, Christine I Chen, MD FRCP(C), Dan T. Vogl, MD, Erkan Baloglu, William Senapedis, PhD, Joel Ellis, PhD, Tony Williams, MD, Sharon Shacham, PhD MBA, Michael G. Kauffman, MD PhD

Blood (2017) 130 (Supplement 1): 3134.

https://doi.org/10.1182/blood.V130.Suppl_1.3134.3134

Published: 2017

Journal Articles

p21-Associated Kinase 4 (PAK4) Addiction in Multiple Myeloma: A Potential Therapeutic Application with Enhanced Activity in FGFR3 Expressing Myeloma

Mariateresa Fulciniti, PhD, Joaquin Martinez Lopez, MD PhD, William Senapedis, PhD, Stefania Oliva, MD, Raphaël Szalat, MD, Mehmet K. Samur, PhD, Rao H Prabhala, PhD, Kenneth C. Anderson, MD, Nikhil C Munshi, MD

Blood (2016) 128 (22): 3302.

https://doi.org/10.1182/blood.V128.22.3302.3302

Published: 2016

Journal Articles

Synergistic Anti-Tumor Effect of KPT-8602, a Second Generation Selective Inhibitor of Nuclear Export (SINE) Compound, and Panobinostat, a Pan-Histone Deacetylase (HDAC) Inhibitor in Multiple Myeloma

Christian Argueta, PhD, Hua Chang, PhD, Trinayan Kashyap, MS, Sivan Elloul, PhD, Sharon Friedlander, PhD, Margaret S. Lee, PhD, Michael Kauffman, MD PhD, Sharon Shacham, PhD MBA, William Senapedis, PhD, Erkan Baloglu, PhD MBA

Blood (2016) 128 (22): 3298.

https://doi.org/10.1182/blood.V128.22.3298.3298

Published: 2016

Journal Articles

Efficacy of Selinexor Is Dependent on IκB-α Expression and NF-Kb Deactivation in Multiple Myeloma Cells

Trinayan Kashyap, MS, Boris Klebanov, MA, MS, Christian Argueta, PhD, Margaret S. Lee, PhD, Sharon Shacham, PhD MBA, Michael Kauffman, MD PhD, Yosef Landesman, PhD, William Senapedis, PhD

Blood (2016) 128 (22): 5660.

https://doi.org/10.1182/blood.V128.22.5660.5660

Published: 2016

Journal Articles

Combination of Selective Inhibitor of Nuclear Export (SINE) Compounds, Selinexor and KPT-8602, with Venetoclax (ABT-199) Displays Enhanced Activity in Leukemia and Large Cell Lymphoma

Melissa A. Fischer, PhD, Sharon Friedlander, PhD, Leah Hogdal, PhD, Pia Arrate, Hua Chang, PhD, Trinayan Kashyap, MS, Christian Argueta, PhD, Boris Klebanov, MA, MS, William Senapedis, PhD, Erkan Baloglu, PhD MBA, Margaret S. Lee, PhD, Sharon Shacham, PhD MBA, Michael R. Savona, MD

Blood (2016) 128 (22): 3949.

https://doi.org/10.1182/blood.V128.22.3949.3949

Published: 2016

Journal Articles

A Phase 1/2 Study of the Second Generation Selective Inhibitor of Nuclear Export (SINE) Compound, KPT-8602, in Patients with Relapsed Refractory Multiple Myeloma

R. Frank Cornell, MD MS, Adriana C Rossi, MD, MSc, Rachid Baz, MD, Craig C Hofmeister, Chaim Shustik, MD, Joshua R. Richter, MD, Christine Chen, MD, Dan T. Vogl, MD, Sharon Shacham, PhD MBA, Erkan Baloglu, PhD MBA, William Senapedis, PhD, Joel Ellis, PhD, Sharon Friedlander, PhD, Cassandra Choe-Juliak, MD, Christopher L Cubitt, PhD, Joel G Turner, PhD, Daniel Sullivan, MD MS, Michael Kauffman, MD PhD

Blood (2016) 128 (22): 4509.

https://doi.org/10.1182/blood.V128.22.4509.4509

Published: 2016

Journal Articles

Combination of Selinexor and the Proteasome Inhibitor, Bortezomib Shows Synergistic Cytotoxicity in Diffuse Large B-Cells Lymphoma Cells In Vitro and In Vivo

Trinayan Kashyap, MS, Irfana Muqbil, Amro Aboukameel, Boris Klebanov, MA, MS, Ramzi Mohammad, PhD, Asfar Sohail Azmi, PhD, William Senapedis, PhD, Sharon Shacham, PhD MBA, Michael Kauffman, MD PhD, Yosef Landesman, PhD

Blood (2016) 128 (22): 4131.

https://doi.org/10.1182/blood.V128.22.4131.4131

Published: 2016

Journal Articles

Next Generation XPO1 Inhibitor KPT-8602 for the Treatment of Drug-Resistant Multiple Myeloma

Joel G Turner, PhD, Jana L Dawson, BS, Christopher L Cubitt, PhD, Erkan Baluglo, PhD, Steven Grant, MD, Yun Dai, PhD, Kenneth H Shain, MD PhD, William S. Dalton, PhD MD, Sharon Shacham, William Senapedis, PhD, Daniel M Sullivan, MD

Blood (2015) 126 (23): 1818.

https://doi.org/10.1182/blood.V126.23.1818.1818

Published: 2015

Journal Articles

Recurrent Mutations of the Exportin 1 Gene ( XPO1 ) in Primary Mediastinal B-Cell Lymphoma: A Lysa Study

Fabrice Jardin, MD PhD, Anais Pujals, PhD, Laura Pelletier, PhD, Elodie Bohers, PhD, Vincent Camus, Sylvain Mareschal, Sydney Dubois, Marlène Ochman, MD, Francois Lemonnier, MD, Pierre-Julien Viailly, Philippe Bertrand, PhD, Catherine Maingonnat, Alexandra Traverse-Glehen, Philippe Gaulard, MD PhD, Diane Damotte, MD PhD, Richard Delarue, MD, Corinne Haioun, MD PhD, Yosef Landesman, PhD, William Senapedis, PhD, Christian Argueta, PhD, Gilles Andre Salles, MD PhD, Jean-Philippe Jais, MD PhD, Martin Figeac, PhD, Christiane Copie-Bergman, MD PhD, Thierry Molina, Jean-Michel Picquenot, PhD, Marie Cornic, Thierry Fest, MD PhD, Noel Milpied, Emilie Lemasle, MD, Aspasia Stamatoullas, MD, Peter Moeller, MD, Martin JS Dyer, MA, DPhil, FRCP, FRCPath, Christer Sundstrom, MD PhD, Christian Bastard, MD PhD, Hervé Tilly, MD PhD, Karen Leroy, MD PhD

Blood (2015) 126 (23): 129.

https://doi.org/10.1182/blood.V126.23.129.129

Published: 2015

Journal Articles

Nuclear Export Inhibitor KPT-8602 Is Highly Active Against Leukemic Blasts and Leukemia-Initiating Cells in Patient-Derived Xenograft Models of AML

Julia Etchin, PhD, Alla Berezovskaya, Amy Saur Conway, Weihsu Claire Chen, PhD, Erkan Baloglu, PhD, Yosef Landesman, PhD, William Senapedis, PhD, Joel Ellis, PhD, Dilara McCauley, PhD, Richard M. Stone, MD, Ilene Galinsky, ANP, Daniel J. DeAngelo, MD PhD, Michael Kauffman, Sharon Shacham, Jean C.Y. Wang, MDPhD, A. Thomas Look, MD

Blood (2015) 126 (23): 326.

https://doi.org/10.1182/blood.V126.23.326.326

Published: 2015

Journal Articles

In Vitro and In Vivo Anti-Leukemic Effects of KPT-9274, a Reported PAK4 Allosteric Modulator, in Acute Myeloid Leukemia: Promising Results Justifying Further Development in This Disease

Shaneice Mitchell, BS, Shelley Orwick, BS, Matthew Cannon, BS, Virginia M. Goettl, DVM , PhD, Taylor D. LaFollette, Erkan Baloglu, PhD, William Senapedis, PhD, Alison R. Walker, MD, Bhavana Bhatnagar, Alice S. Mims, MD, Rebecca B. Klisovic, MD, Sumithira Vasu, MBBS, William Blum, MD, David M. Lucas, PhD, James S. Blachly, MD, Ramiro Garzon, MD, Clara D. Bloomfield, MD, Rosa Lapalombella, PhD, John C. Byrd, MD

Blood (2015) 126 (23): 2471.

https://doi.org/10.1182/blood.V126.23.2471.2471

Published: 2015

Journal Articles

Dissecting Signaling Network Responses to PAK4 Allosteric Modulators (PAMs) in Cell Subsets within Primary Human Acute Myeloid Leukemia Samples

Paul Brent Ferrell, Jr., MD, William Senapedis, PhD, Alexander Cook, Erkan Baloglu, PhD, Yosef Landesman, PhD, Jonathan Michael Irish, PhD, Michael R. Savona, MD

Blood (2015) 126 (23): 3686.

https://doi.org/10.1182/blood.V126.23.3686.3686

Published: 2015

Journal Articles

Cytoskeleton Regulator PAK4 Plays a Role in Growth and Survival of Myeloma with a Potential Therapeutic Intervention Using PAK4 Allosteric Modulators (PAMs)

Mariateresa Fulciniti, PhD, Rajya Lakshmi Bandi, BS, Nicola Amodio, PhD, Antonia Cagnetta, MD, William Senapedis, PhD, Erkan Baloglu, PhD, Kenneth C. Anderson, MD, Nikhil C. Munshi, MD

Blood (2014) 124 (21): 3381.

https://doi.org/10.1182/blood.V124.21.3381.3381

Published: 2014

Journal Articles

In Vitro and in Vivo Quantification of Exportin-1 (XPO1) Occupancy By the Oral Selective Inhibitor of Nuclear Export (SINE) Selinexor in Multiple Myeloma, Acute Myeloid Leukemia, and Healthy PBMCs

Marsha Crochiere, PhD, Boris Klebanov, M.A., MsC, Erkan Baloglu, PhD, Ori Kalid, PhD, Trinayan Kashyap, MSc, William Senapedis, PhD, Diego del Alamo, BS, Tami Rashal, MD, Sharon Tamir, PhD, Dilara McCauley, PhD, Robert Carlson, PhD, Michael Savona, MD, Michael Kauffman, MD PhD, Sharon Shacham, PhDMBA, Yosef Landesman, PhD

Blood (2014) 124 (21): 5196.

https://doi.org/10.1182/blood.V124.21.5196.5196

Published: 2014

Journal Articles

Novel Selective Orally Bioavailable Small Molecule PAK4 Allosteric Modulators (PAMs) Display Anti-Tumor Activity in Vitro and in Vivo in Hematological Malignancies

William Senapedis, PhD, Ryan George, PhD, Dilara McCauley, PhD, Joel Ellis, PhD, Marsha Crochiere, PhD, Michael Savona, MD, Sharon Shacham, PhD MBA, Yosef Landesman, PhD, Erkan Baloglu, PhD

Blood (2014) 124 (21): 2208.

https://doi.org/10.1182/blood.V124.21.2208.2208

Published: 2014

Journal Articles

CRM1 Blockade by Novel Inhibitors of Nuclear Export (SINEs) Inhibits Multiple Myeloma Cell Growth, Osteoclastogenesis, and Myeloma-Induced Osteolysis

Blood (2012) 120 (21): 326.

https://doi.org/10.1182/blood.V120.21.326.326

Published: 2012

Journal Articles

Blockade of Nuclear Export Protein CRM1 (chromosomal region maintenance 1, XPO1) by a Novel, Potent and Selective CRM1 Inhibitor KPT-185 Induces Significant Antitumor Activity Against Human Multiple Myeloma

Sun-Young Kong, MD, PhD, Yosef Landesman, PhD, Jana Jakubikova, PhD, Michael A. Sellitto, Antonia Cagnetta, MD, Michele Cea, MD, Michelle C. Chen, Francesca Cottini, MD, Douglas W. McMillin, PhD, Chirag Acharya, MD, William Senapedis, PhD, Sharon Shacham, PhD, MBA, Michael Kauffman, MD, PhD, Dilara McCauley, PhD, Jean-Richard Saint-Martin, BS, Nikhil C. Munshi, MD, Paul G. Richardson, MD, Kenneth C. Anderson, MD, Yu-Tzu Tai, PhD

Blood (2011) 118 (21): 2913.

https://doi.org/10.1182/blood.V118.21.2913.2913

Published: 2011

NARROW

NAMPT Inhibitor KPT-9274 Selectively Targets Self-Renewal Capacity in Acute Myeloid Leukemia

PAK4 Inhibition Impacts Growth and Survival, and Increases Sensitivity to DNA-Damaging Agents in Waldestrostom Macroglobulinemia

Eltanexor (KPT-8602), a Second-Generation Selective Inhibitor of Nuclear Export (SINE) Compound, in Patients with Refractory Multiple Myeloma

p21-Associated Kinase 4 (PAK4) Addiction in Multiple Myeloma: A Potential Therapeutic Application with Enhanced Activity in FGFR3 Expressing Myeloma

Synergistic Anti-Tumor Effect of KPT-8602, a Second Generation Selective Inhibitor of Nuclear Export (SINE) Compound, and Panobinostat, a Pan-Histone Deacetylase (HDAC) Inhibitor in Multiple Myeloma

Efficacy of Selinexor Is Dependent on IκB-α Expression and NF-Kb Deactivation in Multiple Myeloma Cells

Combination of Selective Inhibitor of Nuclear Export (SINE) Compounds, Selinexor and KPT-8602, with Venetoclax (ABT-199) Displays Enhanced Activity in Leukemia and Large Cell Lymphoma

A Phase 1/2 Study of the Second Generation Selective Inhibitor of Nuclear Export (SINE) Compound, KPT-8602, in Patients with Relapsed Refractory Multiple Myeloma

Combination of Selinexor and the Proteasome Inhibitor, Bortezomib Shows Synergistic Cytotoxicity in Diffuse Large B-Cells Lymphoma Cells In Vitro and In Vivo

Next Generation XPO1 Inhibitor KPT-8602 for the Treatment of Drug-Resistant Multiple Myeloma

Recurrent Mutations of the Exportin 1 Gene ( XPO1 ) in Primary Mediastinal B-Cell Lymphoma: A Lysa Study

Nuclear Export Inhibitor KPT-8602 Is Highly Active Against Leukemic Blasts and Leukemia-Initiating Cells in Patient-Derived Xenograft Models of AML

In Vitro and In Vivo Anti-Leukemic Effects of KPT-9274, a Reported PAK4 Allosteric Modulator, in Acute Myeloid Leukemia: Promising Results Justifying Further Development in This Disease

Dissecting Signaling Network Responses to PAK4 Allosteric Modulators (PAMs) in Cell Subsets within Primary Human Acute Myeloid Leukemia Samples

Cytoskeleton Regulator PAK4 Plays a Role in Growth and Survival of Myeloma with a Potential Therapeutic Intervention Using PAK4 Allosteric Modulators (PAMs)

In Vitro and in Vivo Quantification of Exportin-1 (XPO1) Occupancy By the Oral Selective Inhibitor of Nuclear Export (SINE) Selinexor in Multiple Myeloma, Acute Myeloid Leukemia, and Healthy PBMCs

Novel Selective Orally Bioavailable Small Molecule PAK4 Allosteric Modulators (PAMs) Display Anti-Tumor Activity in Vitro and in Vivo in Hematological Malignancies

CRM1 Blockade by Novel Inhibitors of Nuclear Export (SINEs) Inhibits Multiple Myeloma Cell Growth, Osteoclastogenesis, and Myeloma-Induced Osteolysis

Blockade of Nuclear Export Protein CRM1 (chromosomal region maintenance 1, XPO1) by a Novel, Potent and Selective CRM1 Inhibitor KPT-185 Induces Significant Antitumor Activity Against Human Multiple Myeloma

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only